The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Gilead presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Image credit: Shutterstock / Sundry Photography Gilead is set to launch a Phase III trial of its ...

Overall survival data was not yet mature with less than a quarter of the required number of events having occurred. Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human ...

eCOA is utilised for assessing a new drug’s efficacy and safety by gauging the feelings and functioning of participants in clinical trials. Credit: fizkes/Shutterstock. Endpoint data solutions ...

J&J and Protagonist Therapeutics are collectively developing icotrokinra, which is poised to be an immunology blockbuster. Image credit: Emily frost / Shutterstock. Johnson & Johnson (J&J) and ...

Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of rocatinlimab, in ...

AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

The Phase II and Phase III trials show the therapy is effective at dropping blood pressure. Image credit: Good dreams – Studio / Shutterstock. Mineralys Therapeutics’s oral hypertension therapy, ...

The trial is structured for enrolling nearly 350 subjects. Credit: Joyseulay/Shutterstock. PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to ...